替诺福韦单药治疗与替诺福韦联合恩替卡韦联合治疗在HBeAg阳

StephenW

J Med Virol. 2019 Oct 14. doi: 10.1002/jmv.25608. [Epub ahead of print]
Tenofovir monotherapy versus tenofovir plus entecavir combination therapy in HBeAg-positive chronic hepatitis patients with partial virological response to entecavir.
Wang YH1, Liao J1, Zhang DM1, Wu DB1, Tao YC1, Wang ML1, Chen EQ1, Tang H1.
Author information

1
    Center of Infectious Diseases, West China Hospital of Sichuan University, Chengdu, Sichuan, China.

Abstract
AIMS:

The aim of this retrospective study was to compare the efficacy and safety of tenofovir disoproxil fumarate (TDF) monotherapy and TDF+entecavir (ETV) combination therapy for chronic hepatitis B (CHB) patients with partial virological response (PVR) to ETV.
METHODS:

CHB patients with PVR to ETV were switched to TDF monotherapy or TDF+ETV combination therapy. The primary efficacy outcome was virological response(VR), and the secondary efficacy outcomes were HBeAg seroconversion and ALT normalization. The primary safety outcomes were changes in serum creatinine and serum phosphorus levels.
RESULTS:

A total of 143 patients were investigated, including 63 patients in TDF monotherapy group and 80 patients in TDF+ETV combination therapy group. Baseline demographics and clinical characteristics were comparable between groups. The median age of patients was 44.5 years, and 76.2% of them were male. The VR rate in TDF+ETV group was higher than that of TDF group at 48 weeks (88.8% vs 71.4%; P=0.009). At 48 weeks, HBeAg seroconversion rate of TDF+ETV group was higher than that of TDF group (30% vs 15.9%; P=0.049). There was no significant difference in the proportion of patients with elevated ALT in TDF group and TDF+ETV group at 48 weeks (9.5% vs 7.5%, P=0.665). After adjusting the treatment regimen, serum creatinine level increased slightly and serum phosphorus level decreased slightly in both groups.
CONCLUSIONS:

TDF+ETV combination therapy for 48 weeks had higher virological response rate than TDF monotherapy in CHB patients with partial virological response to ETV. This article is protected by copyright. All rights reserved.

This article is protected by copyright. All rights reserved.
KEYWORDS:

antiviral therapy; chronic hepatitis B; combination therapy; entecavir; partial virologic response; tenofovir

PMID:
    31609007
DOI:
    10.1002/jmv.25608

StephenW

J Med Virol。 2019年10月14日.doi：10.1002 / jmv.25608。 [Epub提前发布]
替诺福韦单药治疗与替诺福韦联合恩替卡韦联合治疗在HBeAg阳性慢性肝炎患者中对恩替卡韦有部分病毒学应答。
Wang YH1，Liao J1，Zhang DM1，Wu DB1，Tao YC1，Wang ML1，Chen EQ1，Tang H1。
作者信息

1个
    四川大学华西医院传染病中心，四川成都

抽象
目的：

这项回顾性研究的目的是比较替诺福韦富马酸替诺福韦（TDF）单一疗法和TDF +恩替卡韦（ETV）联合疗法在对ETV有部分病毒学应答（PVR）的慢性乙型肝炎（CHB）患者中的疗效和安全性。
方法：

PVR转ETV的CHB患者转用TDF单一疗法或TDF + ETV联合疗法。主要疗效结果为病毒学应答（VR），次要疗效结果为HBeAg血清转化和ALT正常化。主要的安全性结果是血清肌酐和血清磷水平的变化。
结果：

共调查143例患者，其中TDF单药治疗组63例，TDF + ETV联合治疗组80例。两组之间的基线人口统计学和临床​​特征相当。患者的中位年龄为44.5岁，其中76.2％为男性。 TDF + ETV组的VR率在48周时高于TDF组（88.8％对71.4％； P = 0.009）。 TDF + ETV组在48周时的HBeAg血清转化率高于TDF组（30％比15.9％； P = 0.049）。在48周时，TDF组和TDF + ETV组的ALT升高患者比例没有显着差异（9.5％vs 7.5％，P = 0.665）。调整治疗方案后，两组的血清肌酐水平略有增加，而血清磷水平则略有下降。
结论：

在对ETV有部分病毒学应答的CHB患者中，TDF + ETV联合治疗48周的病毒学应答率高于TDF单一疗法。本文受版权保护。版权所有。

本文受版权保护。版权所有。
关键字：

抗病毒治疗；慢性乙型肝炎联合疗法恩替卡韦部分病毒学应答；替诺福韦

PMID：
    31609007
DOI：
    10.1002 / jmv.25608